NCT02332850View on ClinicalTrials.gov

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

January 21, 2015

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

Isatuximab

Given IV

DRUG

Carfilzomib

Given IV

DRUG

Dexamethasone

Given IV or PO

Trial Locations (6)

10029

Icahn School of Medicine at Mount Sinai, New York

37203

Sarah Cannon Cancer Center, Nashville

80218

Colorado Blood Cancer Institute, Denver

94143

University of California, San Francisco, San Francisco

07601

Hackensack University Medical Center, Hackensack

M5G 2C1

Princess Margaret Cancer Centre, Toronto

Sponsors

Collaborators (2)

Amgen
Sanofi
All Listed Sponsors
collaborator

Amgen

INDUSTRY

collaborator

Sanofi

INDUSTRY

lead

Thomas Martin, MD

OTHER